Cancer Prevention and Care
The physicians at One to One FemaleCare are skilled practitioners in the prevention, evaluation and diagnosis of female cancers. We promote early testing in the effective treatment of female cancers.
BRCA Gene Testing
We offer BRACAnalysis®, the newest blood test, that assesses your risk for hereditary breast and ovarian cancer. A BRACAnalysis® test is a simple blood test that assesses a woman's risk for hereditary breast and ovarian cancers. "BRAC" stands for "Be Ready Against Cancer," and women at a high risk for Hereditary Breast and Ovarian Cancer Syndrome (HBOC) are encouraged to undergo BRACAnalysis testing early and frequently. Doing so allows women who know they are at risk for hereditary breast or ovarian cancer to make informed decisions about their health before cancer has a chance to develop. Women who test positive for the gene mutation may be able to delay cancer's onset; detect it at an earlier, more treatable stage; or prevent it entirely.
Candidates for BRACAnalysis Testing
BRACAnalysis testing is performed to confirm whether or not a woman carries a BRCA1 or BRCA2 gene mutation, which is responsible for causing most hereditary breast and ovarian cancers. A woman who carries either gene has up to an 87 percent chance of developing breast cancer, and up to a 44 percent chance of developing ovarian cancer, by the age of 70.
A woman is considered a suitable candidate for BRACAnalysis testing if she or a close relative, which includes a parent, sibling, child, uncle, aunt, great uncle, great aunt, nephew, niece, grandparent, grandchild, half-sibling or first cousin, meets the following criteria:
- Was diagnosed with breast cancer at or before the age of 50
- Was diagnosed with ovarian cancer
- Was diagnosed with triple-negative breast cancer
Benefits of BRACAnalysis Testing
Whether its results are positive or negative, BRACAnalysis testing provides significant benefits.
Positive Test Result
A woman who tests positive for a BRCA1 or BRCA2 mutation can have a treatment plan created for her specific medical circumstances, which maximizes the quality of her care. And, by diagnosing the potential for breast or ovarian cancer, her outcome may be improved and her medical costs reduced. A positive result also means that other family members can be counseled about the possibility of being BRCA1/BRCA2 carriers.
Negative Test Result
A woman who tests negative for a BRCA1 or BRCA2 gene mutation can stop worrying that she is at a higher risk for developing breast or ovarian cancer than women without it. And for a woman who has tested negative but has family members who have tested positive, unnecessary interventions on her behalf can be avoided.
The COLARIS® test assesses a person's risk of developing hereditary colorectal cancer, and, for women, the risk of developing hereditary uterine or ovarian cancer. This genetic test is designed to be taken by those with a personal or family history of colorectal adenomas, and by those who develop colorectal or uterine cancer before the age of 50. Assuming mutations in certain gene markers are found, taking a COLARIS test may allow for a more proactive approach to possible later-in-life diagnoses of these and other cancers.
Purpose of COLARIS Testing
Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is the most common form of hereditary colon cancer. HNPCC is estimated to account for 3 to 5 percent of all colorectal cancers. The COLARIS test is designed to find the gene markers associated with HNPCC. Mutations in certain genes mean a person has a higher risk of developing certain cancers, including:
- Colorectal cancer
- Uterine cancer
- Ovarian cancer
- Stomach cancer
Sebaceous adenomas, which are noncancerous tumors of an oil-producing gland, are also more common in those with Lynch syndrome.
Taking the test is extremely simple, requiring only that a blood sample, or oral rinse sample, be taken and then tested for mutations within the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes, which are responsible for HNPCC and related cancers. A person who has a mutation in even one of those genes is considered to have HNPCC.
Benefits of COLARIS Testing
Should gene mutations be found, the benefit of COLARIS testing is that it enables the development of a patient-specific medical-management plan that may reduce the risk of cancer. COLARIS testing may help a patient to:
- Begin cancer screening at an earlier age
- Opt for risk-reducing medications and preventive surgery
- Prevent a second cancer if one has already been diagnosed
- Improve outcomes and reduce medical costs through early intervention
Call the office today to find out more about our OB-GYN Services